Comparison of the Effects of Repaglinide and Metformin on Glucose Excursions
Status:
Unknown status
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This is a 17 week, randomized, single center, open-label, parallel-group study to compare
glucose excursions and other efficacy and safety parameters of repaglinide thrice daily or
metformin thrice daily in newly diagnosed type 2 diabetes subjects in China.